Hasan Çağrı Yıldırım, Yasin Kutlu, Emel Mutlu, Musa Barış Aykan, Mustafa Korkmaz, Selim Yalçın, Teoman Şakalar, Özde Melisa Celayir, Erkan Kayıkçıoğlu, Ferit Aslan, Emre Hafızoğlu, Yunus Emre Altıntaş, Merve Keskinkılıç, Elvin Chalabiyev, Abdussamet Çelebi, Bengü Dursun, Caner Kapar, Miraç Özen, Ömer Acar, Özgecan Dülgar, Engin Kut, Sedat Biter, Fatih Kus, Elvina Almuradova, Atike Pınar Erdoğan, Seray Saray, Deniz Can Güven, Eda Tanrıkulu Şimşek, Necdet Üskent, Yasemin Kemal, Burcu Çakar, Özgür Açıkgöz, Saadettin Kılıçkap, Sercan Aksoy
INTRODUCTION: Male breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients. We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer...
February 4, 2024: International Journal of Clinical Oncology